Professional Seasonal Analysis for Trading

Prelude Therapeutics Incorporated - Common Stock (PRLD)

Seasonality Analysis

Stocks 6 Years Analyzed

Prelude Therapeutics Incorporated - Common Stock Annual Seasonality Statistics

12.94%
Avg Annual Return
42.8%
Avg Monthly Win Rate
5/12
Positive Months
6
Years Analyzed

Prelude Therapeutics Incorporated - Common Stock Monthly Seasonality Performance

Month Avg Return Win Rate Strength
January -10.86%
17%
Very Weak
February -0.38%
33%
Very Weak
March -2.78%
50%
Weak
April 4.11%
50%
Weak
May -7.48%
20%
Very Weak
June -3.17%
40%
Weak
July 11.87%
40%
Weak
August 18.86%
80%
Very Strong
September -10.35%
33%
Very Weak
October WORST -19.28%
33%
Very Weak
November 5.18%
50%
Weak
December BEST 27.20%
67%
Strong

Prelude Therapeutics Incorporated - Common Stock 2026 vs Historical Pattern

Current Position
100
Historical Avg Position
45.17
Deviation
+54.83
Performance
Significantly Above Average

Prelude Therapeutics Incorporated - Common Stock Interactive Seasonality Chart

Interactive Seasonality Chart

Unlock the full interactive seasonality chart for PRLD with overlay patterns, custom date ranges, and more.

Create Free Account

Prelude Therapeutics Incorporated - Common Stock Pattern Scanner

Pattern Scanner

Discover recurring patterns, anomalies, and statistically frequent setups.

Create Free Account

Prelude Therapeutics Incorporated - Common Stock Seasonal Historical Performance

Historical Performance

See historical average returns for PRLD across multiple timeframes.

Create Free Account

About Prelude Therapeutics Incorporated - Common Stock (PRLD) Seasonality

Prelude Therapeutics Incorporated - Common Stock (PRLD) has been analyzed using 6 years of historical data to identify seasonal patterns. Classified under Stocks, Prelude Therapeutics Incorporated - Common Stock shows distinct seasonal tendencies based on historical data.

The strongest month for Prelude Therapeutics Incorporated - Common Stock is historically December, with an average return of 27.20% and a win rate of 67%. Conversely, October tends to be the weakest month, averaging -19.28% return.

Looking at the full calendar year, Prelude Therapeutics Incorporated - Common Stock has an average annual return of 12.94% with an overall monthly win rate of 42.8%. Out of 12 months, 5 typically show positive average returns.

The seasonal pattern for Prelude Therapeutics Incorporated - Common Stock has a consistency score of 55.1 (Fair), based on 7 years of data. Higher consistency means the seasonal pattern has been more reliable across different market conditions.

Prelude Therapeutics Incorporated - Common Stock Seasonality FAQ

What is the best month to buy Prelude Therapeutics Incorporated - Common Stock (PRLD)?

Historically, December has been the best month for Prelude Therapeutics Incorporated - Common Stock, with an average return of 27.20% and a win rate of 67%. However, past performance does not guarantee future results.

What is the worst month for Prelude Therapeutics Incorporated - Common Stock (PRLD)?

Based on historical data, October has been the weakest month for Prelude Therapeutics Incorporated - Common Stock, with an average return of -19.28%. This is a historical observation and does not guarantee future results.

How reliable is PRLD seasonality data?

The seasonality analysis for Prelude Therapeutics Incorporated - Common Stock is based on 6 years of historical price data. While seasonal patterns can provide useful insights, they should be combined with other forms of analysis. Past patterns do not guarantee future performance.

How can I use Prelude Therapeutics Incorporated - Common Stock seasonality in my trading?

Use Prelude Therapeutics Incorporated - Common Stock (PRLD) seasonality as one factor in your analysis. Identify historically strong and weak months, combine with other research methods. SeasOptima provides premium tools including interactive charts, pattern scanning, and historical performance data for deeper analysis.

More Stocks Seasonality Analysis

Statistical information based on historical data. Does not constitute investment advice or recommendation. Past performance does not guarantee future results.